British biopharma firm GSK buys Aiolos Bio
Aiolos Bio focuses on unmet treatment needs of patients with respiratory and inflammatory conditions
FILE PHOTO
ISTANBUL
The British biopharma giant GSK completed the acquisition of clinical-stage biopharmaceutical company Aiolos Bio for some $1.4 trillion, according to a press release on Thursday.
Aiolos Bio focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions, GSK said in a press release.
The acquisition of the firm includes "AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma."
"AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation," it added.
According to a purchasing deal between companies, GSK will pay $1 billion for upfront payment and "up to $400 million in certain success-based regulatory milestone payments."
Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.
